Ah, in my clinic, a generic is like buying chhatua from the local mill—chemically identical to the brand, so it's straightforward. But a biosimilar is like asking for a specific variety of mango—similar, but made from a living cell, so we say "no clinically meaningful difference" to mean it works the same in the body, with no extra risk. Those Indian biosimilars for adalimumab and rituximab have been a blessing, cutting costs by half sometimes, letting me put more patients on therapy. I see it in the relief of a mother who can now afford her son's rheumatoid arthritis injection, where before she would have quietly sold her paar.
#athletics#track-and-field
Jump in to reply — no account needed.